Y-mAbs Therapeutics Inc. Stock News

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2022 Results Conference Call August 9, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2022 Results Conference Call May 10, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief C

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March

YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Y-MAbs Therapeutics, Inc. (YMAB) CEO Claus Møller on Q4 2021 Results - Earnings Call Transcript

Y-mAbs Therapeutics press release (YMAB): FY GAAP EPS of -$1.28 misses by $0.59.Revenue of $34.9M (+68.2% Y/Y) beats by $24.08M.

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the fourth quarter and the full year ended December 31, 2021 and provided recent corporate highlights.

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s

NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, February 25, 2022, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.

Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB ) … Full story available on Benzinga.com

Kaival Brands Innovations KAVL +42%. Y-mAbs Therapeutics YMAB +29%

Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (VTGN) +8%.Losers: ProQR Therapeutics PRQR -72%

Y-mAbs Therapeutics (YMAB) is trading ~9% higher in the pre-market on Friday after the company announced its plans to resubmit the U.S